| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Elahe A Mostaghel | |
| P2860 | cites work | The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases | Q21285041 |
| Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor | Q22254190 | ||
| Type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in the adrenal reticularis | Q24311152 | ||
| Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study | Q24596926 | ||
| The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders | Q24613957 | ||
| Identification of the molecular switch that regulates access of 5alpha-DHT to the androgen receptor | Q24679336 | ||
| Abiraterone in the treatment of metastatic castration-resistant prostate cancer | Q26853635 | ||
| Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme | Q28115363 | ||
| Differential regulation of two uridine diphospho-glucuronosyltransferases, UGT2B15 and UGT2B17, in human prostate LNCaP cells | Q28242235 | ||
| UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells | Q28248233 | ||
| Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase | Q28295989 | ||
| Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium | Q28303858 | ||
| 11{beta}-Hydroxysteroid dehydrogenase 2 in rat leydig cells: its role in blunting glucocorticoid action at physiological levels of substrate | Q28571514 | ||
| Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist | Q28609380 | ||
| Increased survival with enzalutamide in prostate cancer after chemotherapy | Q29617511 | ||
| Targeted androgen pathway suppression in localized prostate cancer: a pilot study | Q30563985 | ||
| Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer | Q30835299 | ||
| Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer | Q33235187 | ||
| Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy | Q33775549 | ||
| Molecular characterization of a first human 3(alpha-->beta)-hydroxysteroid epimerase | Q33909706 | ||
| Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system | Q41827081 | ||
| Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone | Q43264893 | ||
| Biosynthesis of dihydrotestosterone by a pathway that does not require testosterone as an intermediate in the SZ95 sebaceous gland cell line | Q43265330 | ||
| A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens | Q44507804 | ||
| Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma | Q44569677 | ||
| 5α-reduced C21 steroids are substrates for human cytochrome P450c17 | Q44604937 | ||
| Simultaneous determination of androstenedione, 11beta-hydroxyandrostenedione, and testosterone in human plasma by stable isotope dilution mass spectrometry | Q46129165 | ||
| Apparent mineralocorticoid excess syndrome in a Brazilian boy caused by the homozygous missense mutation p.R186C in the HSD11B2 gene. | Q46147309 | ||
| Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer | Q46549099 | ||
| Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease | Q46716649 | ||
| Radioimmunoassay of plasma androstenedione, testosterone and 11β-hydroxy androstenedione after chromatography on Lipidex-5000 (Hydroxyalkoxypropyl sephadex) | Q46723509 | ||
| Endogenous selective inhibitors of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2 of adrenal origin | Q46724003 | ||
| Cyp11b1 is induced in the murine gonad by luteinizing hormone/human chorionic gonadotropin and involved in the production of 11-ketotestosterone, a major fish androgen: conservation and evolution of the androgen metabolic pathway | Q46830604 | ||
| Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites | Q46849827 | ||
| Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. | Q47759846 | ||
| The zona reticularis is the site of biosynthesis of dehydroepiandrosterone and dehydroepiandrosterone sulfate in the adult human adrenal cortex resulting from its low expression of 3 beta-hydroxysteroid dehydrogenase. | Q55066706 | ||
| Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer | Q60156266 | ||
| Androgens, adrenal androgen precursors, and their metabolism in untreated primary tumors and lymph node metastases of human prostatic cancer | Q69851591 | ||
| Characterization of Chinese hamster ovary cell lines expressing human steroid 5 alpha-reductase isozymes | Q70469417 | ||
| 11 beta-Hydroxysteroid dehydrogenase and tissue specificity of androgen action in human prostate cancer cell LNCaP | Q72061779 | ||
| Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells | Q73202210 | ||
| Cellular localization of mRNA expression of enzymes involved in the formation and inactivation of hormonal steroids in the mouse prostate | Q80601140 | ||
| Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease | Q33984042 | ||
| 5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression | Q34183936 | ||
| Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer | Q34204078 | ||
| Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes | Q34484977 | ||
| Liquid chromatography-tandem mass spectrometry analysis of human adrenal vein corticosteroids before and after adrenocorticotropic hormone stimulation | Q34702937 | ||
| Dissecting human adrenal androgen production | Q34750773 | ||
| Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer | Q34786897 | ||
| Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. | Q34798892 | ||
| Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance | Q35083279 | ||
| Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants | Q35249697 | ||
| Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors | Q35532230 | ||
| Estrogen receptor β and 17β-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer | Q35647502 | ||
| Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone | Q35808422 | ||
| The backdoor pathway to dihydrotestosterone | Q35935852 | ||
| Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells | Q36306950 | ||
| Liquid chromatography-tandem mass spectrometry analysis of human adrenal vein 19-carbon steroids before and after ACTH stimulation | Q36663040 | ||
| Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth | Q36876865 | ||
| Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors | Q36937170 | ||
| Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications | Q37159878 | ||
| The effects of ACTH on steroid metabolomic profiles in human adrenal cells | Q37174282 | ||
| Non-traditional metabolic pathways of adrenal steroids | Q37249423 | ||
| Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit | Q37620953 | ||
| 11β-hydroxyandrostenedione returns to the steroid arena: biosynthesis, metabolism and function. | Q38156007 | ||
| Highly potent and selective nonsteroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases. | Q39125210 | ||
| 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer? | Q39125731 | ||
| 11β-hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5α-reductase yielding 11β-hydroxy-5α-androstanedione | Q39150161 | ||
| The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma | Q39462306 | ||
| Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer. | Q39671556 | ||
| The androgen axis in recurrent prostate cancer | Q39675435 | ||
| 5alphaDH-DOC (5alpha-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer | Q39691064 | ||
| Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines | Q39858353 | ||
| Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. | Q40106064 | ||
| The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor | Q40595377 | ||
| Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. | Q40812297 | ||
| Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. | Q40827351 | ||
| Androgen metabolism in the human prostatic cancer cell line LNCaP. | Q41437551 | ||
| Effects of adrenocorticotropin on adrenal and plasma 11 beta-hydroxyandrostenedione in the guinea pig and determination of its relative androgen potency | Q41583165 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivatives | Q6937225 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | androgen receptor | Q416601 |
| prostate neoplasm | Q56014511 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 602-13 | |
| P577 | publication date | 2014-01-01 | |
| 2014-06-03 | |||
| P1433 | published in | International Journal of Biological Sciences | Q6051326 |
| P1476 | title | Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation | |
| P478 | volume | 10 |
| Q26795625 | Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer |
| Q39227656 | Androgen Signaling in Prostate Cancer |
| Q38534949 | Androgen receptor aberrations in the era of abiraterone and enzalutamide |
| Q42702095 | Biological and clinical significance of androgens and androgen receptor in prostate cancer |
| Q42377108 | Clinical relevance of androgen receptor alterations in prostate cancer |
| Q42317209 | Progress in Understanding What Is Being Statin(ed) in Prostate Cancer |
| Q58750423 | Resurrecting FUS: Adrenal Androgens as an Ultimate Cause of Hematuria, Periuria, Pollakuria, Stranguria, Urolithiasis and Obstruction in Neutered Cats |
| Q64985381 | The desA and desB genes from Clostridium scindens ATCC 35704 encode steroid-17,20-desmolase. |
| Q34525556 | The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature. |
| Q51193265 | The role of sex steroid hormones in benign prostatic hyperplasia. |
| Q26795611 | Therapy escape mechanisms in the malignant prostate |
Search more.